BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Gynesonics Receives the CE-Mark for the VizAblateTM System to Treat Uterine Fibroids


1/6/2011 8:18:08 AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Gynesonics, Inc., a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids, announced today that the company has received the CE mark for its VizAblateTM System. The VizAblateTM System is intended to provide gynecologists with an incision-less procedure for the treatment of uterine fibroids associated with heavy menstrual bleeding. The VizAblateTM System is a transcervical device that combines ultrasound image guidance with radiofrequency ablation to treat fibroids in an outpatient setting. Symptoms from uterine fibroids have been reported to affect as many as 24 million women in the European Union.

“The CE mark is an important milestone for the VizAblateTM System,” said Darrin Uecker, President and CEO of Gynesonics. “We are very pleased with our progress throughout 2010, and the CE mark positions us to expand our clinical base and begin commercialization in the European Union where there is strong demand from gynecologists for our product.”

“The VizAblateTM System provides gynecologists with a unique solution for treating uterine fibroids,” said Jose Gerardo Garza-Leal MD, Professor at the Universidad Autónoma de Nuevo León in Monterrey, Mexico and Principal Investigator for the VizAblateTM clinical studies that were completed in support of the CE mark. “The VizAblateTM transcervical procedure is straightforward to perform and requires no incisions, making it appealing to gynecologists and their patients, especially when the primary option may be a hysterectomy.”

As many as 3 out of 4 women will have fibroids during their reproductive life and, though not all will experience symptoms, it has been estimated that up to 30% will. Symptoms associated with fibroids include heavy menstrual bleeding, pelvic pain and pressure and urinary dysfunction. The most frequent surgical treatment for symptomatic uterine fibroids is hysterectomy, with approximately 250,000 hysterectomies being performed in the United States each year alone for fibroids.

The VizAblate SystemTM is currently available for investigational use only in the United States.

Gynesonics, Inc. is a privately-held company with venture capital investors Abingworth, ATV Capital, and Interwest Partners. The company has offices in Redwood City, CA.

For additional information visit www.Gynesonics.com or contact:

Darrin Uecker President and CEO Gynesonics, Inc. Phone: 650-216-3860

Contact:

Gynesonics, Inc. Darrin Uecker, 650-216-3860 President and CEO www.Gynesonics.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES